Loading clinical trials...
Loading clinical trials...
Low Serum Pregnancy Protein 13 Early in Pregnancy Might Predict the Oncoming Gestational Hypertensive Disorders, Especially Early-onset Preeclampsia
the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.
Age
21 - 33 years
Sex
FEMALE
Healthy Volunteers
No
Banha University
Banhā, El- Qalyobia, Egypt
Start Date
March 12, 2020
Primary Completion Date
March 14, 2021
Completion Date
March 19, 2022
Last Updated
August 26, 2022
138
ACTUAL participants
Estimation of Protein 13
DIAGNOSTIC_TEST
Lead Sponsor
Benha University
NCT06468202
NCT06632379
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions